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ABSTRACT
Clinical responses to bendamustine in chronic lymphocytic leukemia (CLL) are 
highly heterogeneous and no specific markers to predict sensitivity to this drug have 
been reported. In order to identify biomarkers of response, we analyzed the in vitro 
activity of bendamustine and the gene expression profile in primary CLL cells. We 
observed that mRNA expression of CD69 (CD69) and ITGAM (CD11b) constitute the 
most powerful predictor of response to bendamustine. When we interrogated the 
predictive value of the corresponding cell surface proteins, the expression of the 
activation marker CD69 was the most reliable predictor of sensitivity to bendamustine. 
Importantly, a multivariate analysis revealed that the predictive value of CD69 
expression was independent from other clinico-biological CLL features. We also 
showed that when CLL cells were co-cultured with distinct subtypes of stromal cells, 
an upregulation of CD69 was accompanied by a reduced sensitivity to bendamustine. 
In agreement with this, tumor cells derived from lymphoid tumor niches harbored 
higher CD69 expression and were less sensitive to bendamustine than their peripheral 
blood counterparts. Furthermore, pretreatment of CD69 high CLL cases with the B-cell 
receptor (BCR) pathway inhibitors ibrutinib and idelalisib decreased CD69 levels and 
enhanced bendamustine cytotoxic effect. Collectively, our findings indicate that CD69 
could be a predictor of bendamustine response in CLL patients and the combination 
of clinically-tested BCR signaling inhibitors with bendamustine may represent a 
promising strategy for bendamustine low responsive CLL cases.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is 
characterized by the proliferation and progressive 
accumulation of mature clonal B lymphocytes in the 
peripheral blood, bone marrow, and lymphoid tissues. The 
clinical course of the disease is highly heterogeneous, with 
some patients requiring early treatment because of disease 
progression while others have an indolent course that 
does not affect life expectancy [1, 2]. Several biological 
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features, including immunoglobulin heavy chain variable 
region (IGHV) mutational status, cytogenetic abnormalities 
and the expression of ZAP-70, CD38 or CD49d, have been 
related to patient outcome [1]. In recent years, in addition 
to the known alterations in DNA-repair genes (TP53 and 
ATM), next generation sequencing has identified new 
somatic mutations (NOTCH1, SF3B1, BIRC3, POT1, 
MYD88) with predicted functional relevance in CLL [3-6]. 
Despite their relative low frequency, these new mutations 
could in part explain CLL heterogeneity and help in 
identifying clinically relevant groups of patients [4, 5, 7] 
and new targeted therapies in this entity [8, 9].
The standard of care for CLL is a cytotoxic therapy 
that includes fludarabine plus cyclophosphamide with the 
monoclonal antibody rituximab (FCR) [10]. Bendamustine 
is a well-tolerated and less toxic agent that has emerged 
as a feasible therapy for elderly and non-fit CLL patients 
[11]. Several trials have shown its clinical efficacy in 
previously untreated and refractory CLL patients being the 
combination of bendamustine with rituximab one of the 
first-line treatments for elderly patients with CLL lacking 
17p deletion [12-15]. Nowadays, in vitro results and 
ongoing clinical trials have explored the combination of 
bendamustine with new generation monoclonal antibodies 
[16, 17] and novel targeted agents[18-22]. 
Bendamustine is a bifunctional alkylating agent that 
contains a nitrogen mustard group and a benzimidazole 
nucleous, combining the properties of an alkylator and a 
purine analogue. These structural characteristics confer 
the compound a unique mechanism of action, with only 
partial cross-resistance to other alkylating agents and 
antimetabolites [23]. Differences have been observed 
in regard to its effects on DNA repair and cell cycle 
progression. Moreover, bendamustine engages cell death 
through both apoptotic and non-apoptotic pathways, 
thereby retaining activity even in cells with dysfunctional 
apoptotic machinery [24]. Recently, it has been reported 
that some membrane transporters might also contribute to 
the cytotoxic effect of bendamustine [25, 26].
Herein, a high-throughput gene expression analysis 
allows us to identify putative biomarkers that could predict 
clinical response of CLL patients to bendamustine. In 
addition, we propose rational drug combinations to 
overcome resistance to bendamustine.
RESULTS
Correlation of gene expression profile and 
sensitivity to bendamustine
To evaluate sensitivity to bendamustine, primary 
cells from 38 untreated CLL cases were incubated with the 
drug at the physiological dose of 25 μM and cytotoxicity 
was determined after 24 hours by double staining 
with Annexin-V/propidium iodide (PI). As expected, 
the apoptosis induced by bendamustine was highly 
heterogeneous, ranging from 4.9 to 79.2% (Supplemental 
Table S1). In agreement with clinical data of CLL patients 
treated with bendamustine, the only CLL case carrying a 
17p deletion (CLL 32) was resistant to bendamustine.
In order to find potential markers of response to 
bendamustine, we carried out a gene expression profiling 
of these 38 CLL cases and analyzed the differential 
expressed genes between the 10 most sensitive cases, all 
of them with a cytotoxicity higher than 42%, and the 10 
most resistant cases, with response to bendamustine of 
less than 18%. To identify the differentially expressed 
genes (DEGs) between sensitive and resistant samples, 
we applied a supervised analysis using a Rank Products 
through the Multiexperiment Viewer Platform (TM4-
MeV) which is based on a two-class unpaired analysis, 
using a false discovery rate (FDR) below 0.01. Next, 
we discarded those genes with a fold-change below 
1.5. This supervised analysis identified 414 DEGs out 
of 19975, being 238 significantly down-regulated and 
176 up-regulated in the bendamustine resistant group 
(Supplemental Table S2). 
To gain insights into the biologic meaning of the 
differential expression profile between bendamustine-
sensitive and -resistant CLL cases, we conducted a 
functional enrichment analysis using the Ingenuity 
Pathway analysis (IPA) application using a specific filter 
for human B lymphocytes and lymphoma/leukemia cells. 
As shown in Figure 1A, the top biological processes 
enriched with the DEGs were cellular movement (71 
genes), cell-to-cell signaling and interaction (57 genes), 
cellular development (93 genes), cellular growth and 
proliferation (101 genes) and cell death and survival 
(100 genes). The complete list of genes is shown in 
Supplemental Table S3. 
We performed a Gene Set Enrichment Analysis 
(GSEA) using the C2 (curated gene sets) collection from 
the Molecular Signature Database v2.5, with an increasing 
profile analysis, 1000 permutations of gene sets and a 
weighted metric. Thus, we identified two gene signatures 
related to CLL features whose gene expression correlated 
with response to bendamustine (gene sets with an FDR 
below 0.05 were considered). Bendamustine-resistant 
samples were enriched in genes previously found to be 
up-regulated in CD38+ cells [27] whereas bendamustine-
sensitive cases displayed up-regulation of genes down-
regulated in ZAP-70+ CD38+ CLL cases (Figure 1B) [28]. 
Validation of DEGs between bendamustine-
resistant and -sensitive CLL
To validate the gene expression profile results, we 
selected a set of 46 DEGs from the biological functions 
encountered by IPA whose fold-change was above 2. These 
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Figure 1: Gene expression profile of bendamustine-resistant and -sensitive cases. A. Top biological enriched functions (IPA 
analysis) with the DEGs (RP analysis, FDR < 0.01) between the 10 most resistant and the 10 most sensitive cases to bendamustine (fold-
change > 1.5). Relative gene expression levels are color-coded as indicated at the bottom legend. B. GSEA enrichment plots of the CLL 
signatures showing a correlation with sensitivity to bendamustine. NES, normalized enrichment score. C. Validation of the 13 DEGs by 
qRT-PCR in a large cohort of cases (p-value indicated at left). Fold-changes of these genes are displayed for both qRT-PCR and microarray 
analysis in the resistant and sensitive groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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genes were analyzed by qRT-PCR using the Fluidigm 
platform in a cohort of 77 CLL cases. Thirteen genes 
from the selected list displayed an inverse correlation 
with response to bendamustine (Supplemental Table 4). 
CD69 and DUSP1 were the genes with the best significant 
correlation with bendamustine response (P < 0.001), and 
a significant correlation of P < 0.01 was observed for the 
expression of ITGAM, BCL2A1 and FOS. All validated 
genes had a fold-change > 2 between the resistant and 
sensitive groups defined as above, with a similar trend as 
observed in the microarray analysis (Figure 1C).
CD69 expression as a predictor of bendamustine 
response in CLL
With the aim to obtain a predictive gene signature 
of response to bendamustine, we used the gene expression 
data validated by qRT-PCR to estimate the Root Mean 
Squared Error (RMSE) metric of different combination 
of genes as described in Materials and Methods. In order 
to obtain the combination of validated genes that best 
predicts the response to bendamustine, a linear regression 
model was fitted for each combination of one to six genes. 
The best cytotoxicity predictor was a signature composed 
of two genes, the activation marker CD69 and the integrin 
ITGAM, which had the lowest RMSE (14.976) (Table 
2A). The most powerful one-variable predictor was 
ITGAM (RMSE = 15.451), followed by CD69 (RMSE = 
15.849) (Table 2B). CD69 and ITGAM codify for CD69 
and CD11b molecules respectively, both expressed 
mainly on the cell surface. To further validate our results, 
we quantified CD69 and CD11b protein levels by flow 
cytometry in primary cells from 35 of the CLL cases 
studied by qRT-PCR. Then, a second analysis to check the 
predictive value of CD69 and CD11b protein levels was 
performed. CD69 levels (P = 0.004) showed a correlation 
with sensitivity to the drug whereas no correlation was 
observed with CD11b protein expression (Figure 2). These 
results prompted us to focus on the single expression of 
CD69 for further study. Relative CD69 mRNA expression 
levels using a Universal Human Reference RNA as a 
calibrator and expression of CD69 by flow cytometry are 
showed in Supplemental Table 1.
CD69 as an independent marker of response to 
bendamustine in CLL
To confirm the potential value of CD69 as a new 
biomarker of bendamustine response in CLL, we analyzed 
whether its predictive significance was independent from 
the main clinical and biological characteristics of CLL 
cases included in the study (n = 77). Through a Mann 
Whitney U Test we observed that, besides high CD69 
mRNA expression (P = 0.0004), prior treatment history 
(P = 0.0189) was also associated with low response 
to bendamustine. However, a multivariate analysis 
including Rai/Binet stage, previous treatment, presence 
of cytogenetic alterations (11qdel, 17pdel, 13qdel and 
trisomy 12), positivity for the prognostic factors CD49d, 
CD38, ZAP-70, IGHV mutational status and presence 
of recurrent mutations (ATM, TP53, NOTCH1, SF3B1, 
MYD88 and BIRC3), revealed that CD69 mRNA level 
Figure 2: Association of CD69 surface levels with response to bendamustine. Basal percentages of CD69+ A. and CD11b+ B. 
CLL cells were quantified by flow cytometry in 35 CLL cases and correlation with response rates to bendamustine 25 µM at 24 hours was 
analyzed. BDM, bendamustine; **, P < 0.01; NS, not significant.
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Table 1: Clinical and biological characteristics of CLL cases
Variable Category  CLL cases (n = 80)
Age at diagnosis
Median (range) 58.7 (37-80)
Gender (F/M)
Female 22 (27.5%)
Male 58 (72.5%)
Percentage of tumor cells
Median (range) 97 (64-99)
Rai stage
0 38 (47.50%)
I 12 (15%)
II 18 (22.5%)
III 5 (6.25%)
IV 7 (8.75%)
Binet stage
A 51 (63.75%)
B 18 (22.5%)
C 11 (13.75%)
Previous treatment
Untreated 68 (85%)
Treated 12 (15%)
IGVH status
Mutated 46 (57.5%)
Unmutated 33 (41.25%)
Not evaluated 1 (1.25%)
ZAP-70 expression
ZAP-70- 57 (71.25%)
ZAP-70+ 22 (27.5%)
Not evaluated 1 (1.25%)
CD38 expression
CD38- 61 (76.25%)
CD38+ 18 (22.5%)
Not evaluated 1 (1.25%)
CD49d expression
CD49d- 15 (18.75%)
CD49d+  46 (57.5%)
Not evaluated 19 (23.75%)
Cytogenetics
Deletion of 17p 2 (2.5%)
Trisomy 12 8 (10%)
Deletion of 13q 44 (55%)
Deletion of 11q 10 (12.5%)
Normal 20 (25%)
Not evaluated 1 (1.25%)
Recurrent mutations
ATM 7 (8.75%)
SF3B1 5 (6.25%)
NOTCH1 4 (5%)
MYD88 2 (2.5%)
TP53 4 (5%)
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was the only variable with independent predictive value of 
bendamustine in vitro cytotoxicity. These results support 
the predictive value of CD69 expression as an independent 
marker of bendamustine in vitro response in CLL.
CLL microenvironment induces CD69 expression 
and reduces sensitivity to bendamustine
Microenvironment interactions in lymphoid 
tissues are reported to protect tumoral CLL cells against 
the action of conventional chemotherapeutic drugs 
[29, 30]. In particular, CD69 has been shown to be up-
regulated on CLL cells in the tissue microenvironment, 
both in bone marrow (BM) and lymph node (LN) [31]. 
With the hypothesis that CD69 could be involved in the 
development of the resistance to bendamustine mediated 
by the microenvironment, we co-cultured primary CLL 
cells with the human bone marrow-derived stroma 
cell line HS-5 and the human follicular dendritic cell-
like cell line HK. As previously reported [20, 22, 32], 
the presence of microenvironment-mimicking cells 
significantly reduced bendamustine-induced apoptosis 
(HS-5: P = 0.03; HK: P = 0.03; Figure 4A). Importantly, 
we showed that CD69 protein levels were increased when 
CLL cells were co-cultured both with HS-5 and HK cells 
(31.4% and 38.7% of increase, respectively; Figure 3A) 
in comparison to monocultured cells. We also compared 
CD69 surface levels and bendamustine response of tumor 
lymphocytes derived from the three typical anatomic CLL 
compartments: peripheral blood (PB), BM and LN. For 
this purpose, we treated 6 paired PB- and BM-derived 
CLL cells and 6 paired PB- and LN-derived samples with 
bendamustine 25 µM for 24 hours. As shown in Figure 3B, 
BM-resident CLL cells, although not significantly, were 
less sensitive than their respective PB counterparts (P = 
0.06) whereas this trend was significant in LN-resident 
cells (P = 0.03). Accordingly, we found a higher CD69 
expression in tissue-resident CLL cells compared to PB 
samples (mean increase of 40% in BM and 182% in LN) 
(Figure 3B). All these results suggest that the activation 
marker CD69 could exert a role in the resistance to 
bendamustine mediated by the microenvironment.
Table 2: Potential predictor signatures for response to bendamustine obtained by performing an RMSE analysis on 
mRNA data
A: List of the first  10  predictor signatures
Number of variables Variables RMSE
2 CD69, ITGAM 14.976
4 CD69, GADD45B, ITGAM,TNFSF9 14.997
3 CD69, GADD45B, ITGAM 15.041
3 AIF1, CD69, ITGAM 15.099
3 CD69,ITGAM,FOS 15.157
4 AIF1,CD69,GADD45B,ITGAM 15.196
3 CD69,ITGAM,TNFSF9 15.212
3 BCL2A1,CD69,ITGAM 15.213
4 AIF1,CD69,ITGAM,FOS 15.258
3 CD69,DUSP1,ITGAM 15.282
B: List of the first 10  predictor genes
Number of variables Variables RMSE
1 ITGAM 15.451
1 CD69 15.849
1 DUSP1 16.052
1 TNFSF9 16.144
1 AIF1 16.291
1 FOS 16.352
1 BCL2A1 16.514
1 GADD45B 16.568
1 DUSP5 16.571
1 EGR1 16.664
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Figure 3: CD69 as a marker of bendamustine-resistance in lymphoid tissue compartments. A. Percentage of CD69+ CLL 
cells was determined after 24 hours of co-culture with HS-5 or HK cell lines (n = 6; left panels). At this point, bendamustine 25 µM was 
added and cytotoxicity was quantified 24 hours later. Cytotoxicity is referred to the untreated control in each culture condition. Bars 
represent the mean±SEM of all samples analyzed (right panels). *, P < 0.05. B. Basal protein levels of CD69 were determined in bone 
marrow (BM) and lymph node (LN) CLL samples (n = 6; left panels). Cells were exposed to bendamustine 25 µM for 24 hours and 
cytotoxicity was analyzed by triple labelling with anti-CD19 antibody, Annexin-V and PI. Cytotoxicity in each tissue compartment is 
referred to cytotoxicity induced in PB cells. Bars represent the mean±SEM of all samples analyzed (right panels). BDM, bendamustine.
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BCR pathway inhibitors decrease CD69 levels 
and sensitize CD69high CLL cells to bendamustine
The BCR pathway inhibitors ibrutinib and idelalisib 
are showing good clinical activity in CLL, in part by 
reducing the degree of cellular activation [33, 34]. 
Particularly, it has been reported that ibrutinib is able 
to down-modulate CD69 surface levels in the clinical 
setting [34]. Thus, we hypothesized that BCR inhibitors 
could have a role in sensitizing CD69high samples to 
bendamustine. To prove this, we preincubated CLL cells 
expressing high levels of CD69 ( > 30%) with ibrutinib 
1 µM or idelalisib 0.5 µM for 24 hours before adding 
bendamustine for 24 additional hours. Both ibrutinib and 
idelalisib decreased CD69 surface protein expression at 
24 hours (data not shown) and more markedly at 48 hours 
(Figure 4). Importantly, the modulation of this activation 
marker was accompanied by a collaborative antitumor 
effect between both drugs in terms of cytotoxicity. In 
this set of bendamustine resistant CLL cases (14.4±2.5% 
cytotoxicity), ibrutinib induced 18.15±4.7% cytotoxicity 
whereas the combination of both drugs had a more marked 
antitumor effect (36.9±5.2%) (Figure 4A). Similarly, 
idelalisib (16.8±5.1%) also potentiated bendamustine 
activity (36.1±4.9%) (Figure 4B). These results indicate 
that BCR inhibitors may be useful to sensitize CD69high 
CLL cases to bendamustine.
DISCUSSION
Patients with CLL are generally managed with a 
‘watch and wait’ strategy until an indication for treatment 
emerges [10, 35]. The initial standard therapy for 
patients without del(17)(p13.1) is chemoimmunotherapy 
(fludarabine plus cyclophosphamide, bendamustine, 
or chlorambucil) and anti-CD20 antibody (rituximab, 
ofatumumab, or obinutuzumab) that varies based 
on regimen and patient status [11]. Bendamustine 
as monotherapy or in combination with other 
chemotherapeutic agents is currently indicated for 
the treatment of elderly and less fit CLL patients 
Figure 4: BCR pathway inhibitors as a strategy to sensitize CD69high CLL cells to bendamustine. Cells from CD69high CLL 
cases were preincubated for 24 hours with ibrutinib 1 µM A. or idelalisib 0.5 µM B., followed by a 24-hour incubation with bendamustine 
25 µM. Percentage of both CD69+ (left panels) and Annexin-V+ cells (right panels) were quantified at the end point. Cytotoxicity values are 
referred to the untreated control. Bars represent the mean±SEM of all samples analyzed (n = 6) *, P < 0.05. 
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lacking del(17)(p13.1) [12, 15]. The primary action of 
bendamustine is the activation of a DNA damage stress 
response and the inhibition of mitotic checkpoints, leading 
to cell death via mitochondrial apoptosis or mitotic 
catastrophe induction [36-38]. 
The response of CLL cells to bendamustine shows a 
marked variability and the molecular mechanisms related 
to bendamustine resistance remain largely undefined. 
Although it has been observed a lower response to 
bendamustine in cases carrying 17p/p53 alterations, 
this genetic abnormality does not fully account for 
heterogeneity in responsiveness to treatment. Herein, 
we have performed a gene expression high-throughput 
analysis with the aim of identifying putative biomarkers 
that could predict the clinical response of CLL to 
bendamustine. Our results showed that the DEGs between 
the bendamustine-sensitive and -resistant cases belong 
to biological processes related to cell death and survival, 
cellular growth and proliferation. GSEA analysis revealed 
that genes overexpressed in CLL signatures associated 
with poor prognostic factors [27, 28] were similarly 
expressed in bendamustine-resistant cases. Among 
the DEGs, we found that the mRNA expression of the 
activation marker CD69 and the integrin ITGAM were the 
most reliable predictors of resistance to bendamustine in 
CLL cells. However, at protein level only CD69 expression 
correlated with bendamustine-induced cytotoxicity. 
Moreover, a multivariate analysis revealed that CD69 
expression was the only factor that predicts response to 
bendamustine independently from other biological and 
clinical CLL features, pointing out a functional role of this 
protein in the mechanisms of resistance to bendamustine. 
CD69 is a type II integral membrane protein 
belonging to the C-type lectin family of surface receptors 
and is expressed in all bone marrow-derived cells, with 
the exception of erythrocytes [39]. CD69 is not found 
on resting circulating lymphocytes in humans, although 
in vitro cell activation showed rapid induction on human 
T and B lymphocytes This surface protein is commonly 
used as the marker of activated cells, most often in 
lymphocytes and natural killer cells [40]. Recently, it 
has also been described to be a key regulator of immune 
responses and one of the major regulators of lymphocyte 
migration, particularly at the mucosal sites [41]. In CLL, 
CD69 has been reported to be an independent prognostic 
marker that significantly correlates with poor clinical 
and biological prognostic factors such as the number of 
treatment lines, the mutational status of the IGHV genes, 
and the expression of CD38, ZAP-70 and CD49d [42, 
43]. In our study, we confirmed the correlation between 
CD69 and CD38 expression and the association between 
previous treatment and bendamustine cytotoxicity in vitro. 
Of note, the GSEA analysis also showed that those CLL 
cases with high expression of CD69 and low response to 
bendamustine had a similar expression profile of CD38 
and ZAP-70 positive CLL cells [27, 28].
Furthermore, our results provided evidence that 
microenvironment-driven resistance to bendamustine 
is accompanied by the up-regulation of CD69 in CLL 
cells considering both mesenchymal and dendritic cell 
co-culture systems. This cytotoxic protection by the 
microenvironment has been reported previously by our 
group [20, 22] and others [32, 44]. In line with these 
results, we observed that tissue-derived CLL cells had 
higher CD69 expression levels than their peripheral blood 
counterparts as previously reported [31, 45]. Accordingly, 
we demonstrated that both LN- and BM-derived CLL 
cells were less sensitive to bendamustine than their PB 
counterparts. On this basis, we postulate that the in vivo 
bendamustine sensitivity could be explained, at least 
partially, by the microenvironment-mediated induction of 
CD69 expression on CLL cells.
This hypothesis prompted us to test if CD69high 
CLL cells without p53 alterations (CD69 expression 
> 30%)[43] could be sensitized to bendamustine with 
some therapeutic strategy. In this context, it has been 
described that the BTK inhibitor ibrutinib was able to 
decrease CD69 surface levels on CLL cells in vivo [34]. 
We confirmed that ibrutinib is able to down-regulate 
CD69 levels and that bendamustine plus ibrutinib have 
a cooperative antitumor effect. These data agree with the 
promising results reported in clinical trials evaluating the 
safety and the efficacy of ibrutinib in combination with 
bendamustine-based regimens in relapsed CLL [18, 46]. 
As preclinical investigation of the combination of ibrutinib 
and rituximab resulted in an antagonistic effect [47], it is 
conceivable that bendamustine might play an important 
role in the potentiation of ibrutinib effect. Our results 
showed that the PI3Kδ inhibitor idelalisib also decreased 
CD69 levels and enhanced bendamustine-induced 
cytotoxicity in primary CLL cells. In this regard, there 
are ongoing clinical trials evaluating the combination of 
bendamustine-based regimens and idelalisib [48, 49]. We 
can hypothesize that the two approved targeted therapies 
in CLL cells, ibrutinib and idelalisib, although they differ 
considerably from each other, not only in target but also 
in mechanism of action, could facilitate bendamustine 
in vivo activity. By disruption of the microenvironment-
supporting growth, both drugs result in the egress of the 
tumor cells from lymphoid tissues to peripheral blood, 
where microenvironment signals are much weaker 
and bendamustine might exert a greater effect. In this 
sense, experiments in mouse models have reported that 
bendamustine is mainly confined to the extracellular fluid 
and not extensively distributed to tissues [50]. Through 
this mechanism, CLL cells mobilized after treatment with 
ibrutinib could be sensitive to apoptotic-triggering drugs 
[19].
In summary, our results support a role of the 
activation marker CD69 in the resistance of CLL cells 
to bendamustine, suggesting that its surface levels 
could predict response of patients to this compound. 
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Furthermore, we propose that bendamustine efficacy could 
be increased by its combination with the state-of-the-art 
BCR pathway inhibitors ibrutinib or idelalisib, as both 
drugs were able to decrease CD69 levels and therefore 
sensitize CLL cells to bendamustine. These combinations, 
already in clinical trials, could be a potential strategy to 
treat poor prognosis CD69high CLL cases as well as to 
contribute to the achievement of complete remissions 
during treatment with these targeted therapies.
MATERIALS AND METHODS
Isolation and culture of primary cells
Peripheral blood mononuclear cells (PBMCs) from 
80 patients diagnosed with CLL according to the World 
Health Organization criteria [51] were used in this study. 
Clinical and biological data of these cases are summarized 
in Table 1 and detailed in Supplemental Table 1. 
The IGHV gene mutational status was determined 
according to European Research Initiative on CLL (ERIC) 
guidelines [52]. Percentage of tumor cells (CD19+, 
CD5+) and expression of ZAP-70, CD38 and CD49d 
were determined by flow cytometry. The identification of 
cytogenetic aberrations involving 11q22-23 (ATM), 13q14 
and 17p13 (TP53) deletions and trisomy 12 was done 
by fluorescence in situ hybridization (FISH). Recurrent 
mutations were obtained from previous whole genome/
exome sequencing studies [4]. 
Primary cells were isolated from PB or BM samples 
by Ficoll-Paque sedimentation (GE-Healthcare). Primary 
cells from LN were obtained after squirting with RPMI 
1640 (Life Technologies) culture medium using a fine 
needle. Samples were cryopreserved and stored within the 
Hematopathology collection of our institution registered 
at the Biobank from Hospital Clínic-IDIBAPS (R121004-
094). The ethical approval for this project including the 
informed consent of the patients was granted following 
the guidelines of the Hospital Clínic Ethics Committee. 
Thawed cells were cultured in fresh RPMI 1640, 
supplemented with 10% fetal bovine serum (FBS), 2 mM 
glutamine and 50 µg/mL penicillin-streptomycin (Life 
technologies) and cultured in a humidified atmosphere at 
37ºC containing 5% carbon dioxide.
Analysis of cytotoxicity
Primary CLL cells were incubated for 24 hours 
with a physiological dose of 25 µM bendamustine, kindly 
provided by Mundipharma. When indicated, CLL cells 
were pretreated for 24 hours with 0.5 µM of the PI3Kδ 
inhibitor idelalisib and 1 µM of the BTK inhibitor ibrutinib 
(Selleck Chemicals) prior to bendamustine addition. Cell 
viability was quantified by double staining with Annexin-V 
conjugated to fluorescein isothiocyanate (FITC) and PI 
(eBiosciences). For the comparative analysis of response 
in PB, BM and LN compartments, cells were triple-stained 
with phycoerythrin (PE)-conjugated anti-CD19 (Becton 
Dickinson), Annexin-V-FITC and PI. Labeled samples 
were analyzed on an Attune focusing acoustic cytometer 
(Life Technologies). Cytotoxicity (mean ± SEM) was 
calculated as the percentage of Annexin-V-positive cells 
in treated samples relative to the untreated ones.
Gene expression analysis
CD19+ tumor CLL cells were purified from 38 
CLL cases as previously reported [3]. Total RNA was 
isolated from these samples using TRIzol reagent (Life 
Technologies) according to manufacturer’s instructions. 
RNA integrity was examined with the Bioanalyzer 2100 
(Agilent Technologies) and only high quality samples were 
hybridized to Affymetrix GeneChip HT HG-U219 perfect-
match-only (PM) Array Plate, following Affymetrix 
standard protocols. The Expression Console software 
(Affymetrix, Santa Clara, CA, USA) was used to get the 
summarized expression values by the Robust Multi-array 
Analysis (RMA). The raw data have been deposited in the 
Gene Expression Omnibus Database (accession number 
GSE68163).
DEGs were identified by using a Rank Products 
(RP) test through the Multiexperiment Viewer Platform 
(TM4-MeV), which is based on a two-class unpaired 
analysis as previously described [53], using a FDR below 
0.01. Genes with a fold-change below 1.5 were discarded. 
The list of DEGs was used to conduct a functional 
enrichment analysis using the Ingenuity Pathway analysis 
(IPA)(Ingenuity® Systems) and applying a specific filter 
for human B lymphocytes and lymphoma/leukemia cells. 
Gene signatures with an expression pattern 
correlating with sensitivity to bendamustine were 
identified with GSEA version 2.0 (Broad Institute at MIT; 
http://www.broadinstitute.org/gsea/) using the C2 (curated 
gene sets) collection from the Molecular Signature 
Database v2.5. An increasing profile analysis with 1000 
permutations of gene sets and a weighted metric was used. 
Gene sets with an FDR below 0.05 were considered.
Quantitative real-time PCR
Total RNA was isolated as above from CLL cells, 
and complementary DNA was obtained using the Reverse 
Transcription Master Mix (Fluidigm Corporation). 
Samples were processed to Specific Target Amplification 
using the PreAmp Master Mix (Fluidigm Corporation) 
and the corresponding TaqMan Gene Expression Assays 
(Life Technologies). PCR was run as recommended by the 
manufacturer in a 96.96 Dynamic Array-Gene Expression 
IFC (Fluidigm Corporation). The relative expression 
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of each gene was quantified by the comparative cycle 
threshold (Ct) method (∆∆Ct), using GUSB as endogenous 
control and taking as a calibrator the Universal Human 
Reference RNA (Life Technologies).
Quantification of CD69 and CD11b levels by flow 
cytometry
Cell suspensions from PB, LN and BM were 
washed and blocked with 10% mouse serum (Sigma). 
Samples were then stained with anti-CD19-FITC (Becton 
Dickinson), PI, and either anti-CD69-PE or anti-CD11b-
PE (Becton Dickinson) and analyzed in an Attune flow 
cytometer. In each quantification experiment, a constant 
calibrator sample was stained simultaneously. Expression 
data was reported as the percentage of viable CLL cells 
positive for CD69 or CD11b after subtraction of cells 
stained for IgG1 isotype-PE (Becton Dickinson).
Co-culture assays
Human bone marrow-derived mesenchymal cell 
line HS-5 (American Type Culture Collection)(ATCC®, 
CRL 11882™) and human follicular dendritic cell-like 
cell line HK (kindly provided by Dr. Y.S. Choi) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
Life Technologies) and Iscove’s modified Dulbecco’s 
medium (IMDM, Life Technologies), respectively, and 
supplemented as above. Before setting up the experiment, 
HS-5 (2x104 cells) and HK cells (1x104 cells) were 
plated overnight and, once obtained a confluent stromal 
monolayer, CLL cells were added at a 1:10 (HS-5:CLL) 
and 1:20 (HK:CLL) ratio. After 24 hours, CLL cells 
were analyzed for CD69 expression. At that time, 25 µM 
bendamustine was added for 24 hours and CLL viability 
was analyzed by flow cytometry.
Statistical analysis
Spearman correlation was used to evaluate the 
dependence of bendamustine cytotoxicity on gene or 
protein expression. Mann Whitney U Test was used to 
evaluate response differences among unpaired samples 
and Wilcoxon Signed Rank Test was used when the 
samples were paired. These analyses were performed 
using GraphPad Prism 4.0 software (GraphPad Software). 
Multivariate linear regression models were used 
to determine the relationship between sensitivity to 
bendamustine and gene, protein and/or clinical variables. 
Logarithmic transformations were used when necessary to 
correct for non-normal distributions. 
In order to obtain the combination of validated genes 
that best predicts the response to bendamustine, a linear 
regression model was fitted for each combination of one 
to six genes. The RMSE metric was used to compare the 
performance of each model, which was estimated using 
the errorest function in the ipred package of R software 
with 800 bootstrap samples. Normality of the residuals 
was checked for the models with lowest RMSE. Lower 
values of RMSE indicate better fit of the model.
To confirm the independence of candidate predictors 
from clinical variables, a stepwise linear regression with 
backward elimination of the non-significant variables was 
performed. All linear regression models were calculated 
using R software. Statistical significance was considered 
when p-value < 0.05 (* P < 0.05, ** P < 0.01, *** P < 
0.001). 
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